Galectin-9 and T Cell Immunoglobulin Mucin-3 Pathway Is a Therapeutic Target for Type 1 Diabetes-Reference-Cited by-同舟云学术

Galectin-9 and T Cell Immunoglobulin Mucin-3 Pathway Is a Therapeutic Target for Type 1 Diabetes

Published:2012-02-01 Issue:2 Volume:153 Page:612-620
ISSN:0013-7227
Container-title:Endocrinology
language:en
Short-container-title:

Author:

Kanzaki Motoko¹,Wada Jun¹,Sugiyama Koichi¹,Nakatsuka Atsuko¹,Teshigawara Sanae¹,Murakami Kazutoshi¹,Inoue Kentaro¹,Terami Takahiro¹,Katayama Akihiro¹,Eguchi Jun¹,Akiba Hisaya²,Yagita Hideo²,Makino Hirofumi¹

Affiliation:

1. Department of Medicine and Clinical Science (M.K., J.W., K.S., A.N., S.T., K.M., K.I., T.T., A.K., J.E., H.M.), Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan

2. Department of Immunology (H.A., H.Y.), Juntendo University School of Medicine, Tokyo 113-8421, Japan

Publisher

The Endocrine Society

Subject

Endocrinology

Link

http://academic.oup.com/endo/article-pdf/153/2/612/10385293/endo0612.pdf

Reference32 articles.

1. Galectins. Structure and function of a large family of animal lectins.;Barondes;J Biol Chem,1994

2. Galectins: a family of animal β-galactoside-binding lectins.;Barondes;Cell,1994

3. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin.;Wada;J Clin Invest,1997

4. Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin.;Wada;J Biol Chem,1997